Home / Press Release / Pharmaceutical Excipients Market
Published: November 13, 2026

Global Pharmaceutical Excipients Market to Reach US$16.34 Billion by 2034 as Formulation Shifts to Asia and Parenteral Demand Accelerates: Epignosis Insights

Global Pharmaceutical Excipients Market to Reach US$16.34 Billion by 2034 as Formulation Shifts to Asia and Parenteral Demand Accelerates: Epignosis Insights

Epignosis Insights, a market research and brand intelligence consultancy, has released its latest report on the Global Pharmaceutical Excipients Market. The study estimates that the market was valued at US$9.94 billion in 2025 and will reach US$16.34 billion by 2034, expanding at a compound annual growth rate (CAGR) of 5.7% from 2027 to 2034. In volume terms, global excipient consumption is projected to grow from 1,790 thousand tons in 2025 to 2,637 thousand tons by 2034.

The report provides a detailed assessment of market value, consumption volume, installed production capacity, capacity utilization and pricing, segmented by product type, functionality, formulation route and region. It also introduces the Epignosis Insights Competitive Assessment Framework (EICAF) for benchmarking excipient suppliers across ten weighted parameters.

Key Highlights of the Report

  • Market value is forecast to increase from US$9.94 billion in 2025 to US$16.34 billion by 2034.
  • Consumption volume is expected to reach 2,637 thousand tons by 2034, growing at a 4.4% volume CAGR.
  • Installed production capacity is estimated at 2,240 thousand tons in 2025, rising to 3,081 thousand tons by 2034.
  • Average capacity utilization is projected to tighten from 79.9% in 2025 to 85.6% by 2034.
  • Average realized prices are expected to rise from US$5,553 per ton to US$6,196 per ton over the same period.
  • Parenteral excipients are the fastest growing formulation route, at a 7.6% CAGR between 2027 and 2034.

Value Outpacing Volume as the Demand Mix Upgrades

A central finding of the report is that market value is growing more than a full percentage point faster each year than volume. Epignosis Insights attributes this gap to a steady change in what formulators buy. 

Commodity fillers such as lactose, starch and microcrystalline cellulose continue to account for most of the tonnage used in tablets, but spending is shifting toward higher-value materials, including film coating systems, solubility enhancers, co-processed direct compression grades and excipients manufactured to parenteral standards.

"Excipients are often described as inactive ingredients, but their commercial role is anything but passive," said a spokesperson for Epignosis Insights. "Formulators are asking excipients to do more work, whether that means making a poorly soluble molecule bioavailable, protecting a biologic in an injection, or masking taste in a pediatric medicine. That functional demand is what is driving value growth ahead of tonnage."

Asia Pacific Expands Its Share of Global Demand

The report finds that the geography of excipient demand is being redrawn by the movement of generic and contract formulation volume to Asia. Because excipients are consumed where medicines are physically manufactured, regional demand follows formulation capacity. Epignosis Insights estimates that Asia Pacific accounted for 33.5% of global excipient demand by value in 2025 and will reach 38.2% by 2034.

India is a key contributor to this shift, given the growing scale of its formulation exports to highly regulated markets. Products destined for the United States and Europe require excipients with full compendial compliance and documented supply chains, which is pulling Indian formulators toward globally qualified and higher-value grades. North America and Europe continue to grow in absolute terms and retain a disproportionately high share of specialty and parenteral excipient spending.

Capacity Tightening Raises the Stakes for Supply Resilience

On the supply side, the report estimates global installed capacity at 2,240 thousand tons in 2025, with Asia Pacific holding about 44% of the total. Capacity is forecast to rise to 3,081 thousand tons by 2034, but demand is expected to grow slightly faster, lifting average utilization to 85.6%.

Epignosis Insights notes that this tightening is more consequential than it appears. Pharmaceutical-grade plants cannot easily switch products, and each formulator typically registers a specific grade from a specific site in its regulatory dossier. The loss of a single qualified plant can therefore disrupt customers well beyond that plant's share of global capacity. The report concludes that suppliers able to manufacture identical grades across multiple sites are gaining a measurable advantage in long-term supply agreements.

Innovation Channelled into Refinement Rather Than New Molecules

The report identifies the lack of a standalone regulatory pathway for novel excipients as the most significant structural restraint on the market. Because excipients are generally evaluated only as part of a specific drug application, formulators tend to rely on materials with established precedence of use. As a result, much of the industry's innovation is flowing into co-processed combinations, higher-purity grades of established polymers and application support, rather than entirely new chemistries.

Parenteral Formulations Lead Growth

Although oral dosage forms account for 64.0% of 2025 market value, parenteral excipients are forecast to grow at a 7.6% CAGR between 2027 and 2034, the fastest of any route. Demand is supported by the expansion of biologics, peptide therapeutics and long-acting injectables, which require stabilizers, surfactants, buffers, sugars and lipids produced to stringent low-endotoxin specifications.

Competitive Landscape

The report profiles leading suppliers including Roquette (including the former IFF Pharma Solutions), BASF Pharma Solutions, Ashland, Evonik Health Care, DFE Pharma, Colorcon, JRS Pharma, MEGGLE, Merck KGaA, Shin-Etsu Chemical, Lubrizol, Croda, Gattefossé, SPI Pharma, Asahi Kasei, Kerry, Wacker Chemie, Avantor, Sigachi Industries and Ideal Cures. Consolidation has been a defining theme, as suppliers seek to offer formulators broader portfolios through a single qualification relationship.

Under the EICAF methodology, regulatory and quality compliance carries the highest weighting at 15%, followed by manufacturing scale and capacity, supply security and dual sourcing, and product portfolio breadth at 12% each.

Report Coverage

  • By Product Type: Organic Chemicals (Carbohydrates, Petrochemicals, Oleochemicals, Proteins) and Inorganic Chemicals (Calcium Phosphates, Metal Oxides, Calcium Carbonate, Silicates, Halites)
  • By Functionality: Fillers and Diluents, Binders, Coating Agents, Disintegrants, Solubilizers and Emulsifiers, Lubricants and Glidants, Flavoring and Sweeteners, Preservatives, Others
  • By Formulation: Oral, Parenteral, Topical, Others
  • By Region: North America, Europe, Asia Pacific, Latin America, Middle East and Africa

About Epignosis Insights

Epignosis Insights is a Pune-based market research and brand intelligence consultancy delivering data-driven insights to support smarter business decisions. The firm provides B2B market reports, brand tracking studies, pricing trackers, product and innovation research, and customer experience research across industries including healthcare and pharmaceuticals, chemicals and materials, consumer goods, energy, and technology.